The Department of Neurosurgery seeks men and women ages 18-75 with chronic pain resulting from head and/or neck cancer for a research study. The purpose of the study is to determine if focused ultrasound can be used to help relieve chronic pain in patients whose medications are not working well to control their pain.

This study involves a screening and baseline visit followed by a focused ultrasound procedure and post-procedure visits at 1 Day, 1 week, and 3 month. You will be contacted by phone at the 1 month and 6 month time points.

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults with peripheral T-cell lymphoma (PTCL) who have received treatment but the treatment either didn’t work or stopped working. The purpose of this study is to find out whether the combination treatment of romidepsin and oral azacytidine is safe and effective in patients with PTCL.

UVA Health System, Department of Internal Medicine, Division of Endocrinology is conducting a clinical research study. We want to learn more about how the effect of elevated blood sugar after eating a meal affects blood vessels and blood flow to the heart. Eligible participants must be 18-35 years, a non-smoker and healthy, or have Type 1 diabetes.
Healthy control participants will have 2 outpatient visits:
- Screening visit (1 hr.)
- 1 Outpatient admission (5 hrs.)
Type 1 participants will have 3 outpatient visits:
- Screen visit (1hr.)

This single arm study evaluates the use of pre-operative endocrine therapy in women with early stage ER+ breast cancer who are 65 years or older and are recommended for lumpectomy. The purpose of this study is to see if tolerance of pre-operative endocrine therapy helps inform decisions on whether or not to omit radiation. Participants will be treated with the novel approach of 3 months of pre-operative endocrine therapy, so that the participants and providers will have some indication of tolerance prior to making a decision about radiation omission.

The University of Virginia Cancer Center is conducting a clinical research study for women who are adults ages 18 and over, and have low-grade serous ovarian cancer. The purpose of this study to evaluate an investigational drug (VS-6766) alone or in combination with another investigational drug (defactinib) in participants with ovarian cancer. The effects of the investigational drugs alone or in combination will be evaluated for this study.

The University of Virginia Cancer Center is conducting a clinical research study for adults ages 18 and over who have recurrent platinum-resistant ovarian cancer. This study will look at the effects of the combination of two drugs: a kinase inhibitor (Decitabine) and a PARP inhibitor (Olaparib). The goal of the study is to find out if abemaciclib and olaparib can be taken safely together in ovarian cancer that has come back.

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have HER2 (Human Epidermal Growth Factor Receptor 2)-positive breast cancer. The purpose of this study is to determine if T-DXd would be effective in the treatment of HER2-positive early breast cancer in subjects that have already had treatment prior to breast cancer surgery, specifically for subjects that are considered at high risk for their breast cancer to return.

Department of Neurology researchers are building a registry of people interested in studies of Alzheimer’s disease and related dementias. The purpose of the registry is to collect and store contact information and basic health information from potential participants. This information will be used to help decide what studies may be right for you.

You may be eligible if you have memory problems, are a caregiver of someone with memory problems, or are an interested healthy adult (18 years of age or older).

The Neurology Department Memory Disorders Division seeks adults ages 55 to 80 with Early Alzheimer’s Disease for a research study. The purpose of the study is to test the safety and effectiveness of an investigational medicine.

You may be eligible for this study if You:
-Have a diagnosis of Mild Cognitive Impairment or Mild Alzheimer’s Disease
-Have an available study partner who knows you well and agrees to participate
-Are in good general health with stable medications

COMPPARE stands for “A Prospective COMparative Study of Outcomes with Proton and Photon RAdiation in
PRostate CancEr (COMPPARE).” This study, which is funded by the Patient-Centered Outcomes Research
Institute (PCORI) and approved by the University of Florida Institutional Review Board, will compare the
quality of life, side effects, and cure rates for prostate cancer patients treated with proton therapy or photon
therapy.
We will ask 3000 men between the ages of 30-85 across the US who will be treated with either protons or